Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Comment by WalkOverTheStrton May 27, 2024 5:33pm
82 Views
Post# 36059432

RE:RE:RE:Collaboration or Collective Misery

RE:RE:RE:Collaboration or Collective MiseryThe versions before 3.2 were in many cases not great and had too many issues for errors and poor user experience. Part of the sales strategy of the past was selling a not ready for prime time product and then focusing on placements for studies. While it helped get them noticed and have data to back up their claims it wasted time on paying customers. Duke's bums unit pay back was less than a year with the USA insurance reinbursement codes. Hugh stated on the last call the pay back for the units was now around 6-9 months. This will help sell and large logos like Duke and the one in Germany will also. George and Alvira were not suited or experienced in sales. They used a distributor model wherein they made horrible choices - all in USA except Ascend were small shops and the two in Europe were without a ventripoint sales rep for over 9 months. Again shows horrible decision making by GA and Alvira. Having spoken to and seen in 60 days what Hugh is already done it's clear he gets sales and marketing. We are in a much better spot with him and Bart as well as with version 3.2 and soon 4.0 (fall approval or sooner) than we have in years.  
<< Previous
Bullboard Posts
Next >>